首页> 外文期刊>Leprosy review >Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials.
【24h】

Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials.

机译:预防和治疗麻风神经功能损害的皮质类固醇标准化治疗方案的不良事件:“ TRIPOD”试验的结果。

获取原文
获取原文并翻译 | 示例
       

摘要

Reactions in leprosy causing nerve function impairment (NFI) are increasingly treated with standardized regimens of corticosteroids, often under field conditions. Safety concerns led to an assessment of adverse events of corticosteroids, based on data of three trials studying prevention of NFI (the TRIPOD study). A multicentre, randomized, double-blind placebo-controlled trial was conducted in leprosy control programmes in Nepal and Bangladesh. Treatment was with prednisolone according to fixed schedules for 16 weeks, starting in one trial with 20 mg/day (prophylactic regimen: total dosage 1.96 g) and in the other two trials with 40 mg/day (therapeutic regimen: total dosage 2.52 g). Minor adverse events were defined as moon face, fungal infections, acne, and gastric pain requiring antacid. Major adverse events were defined as psychosis, peptic ulcer, glaucoma, cataract, diabetes and hypertension. Also, the occurrence of infected plantar, palmar, and corneal ulceration was monitored, together with occurrence of TB. Considering all three trials together, minor adverse events were observed in 130/815 patients (16%). Of these, 51/414 (12%) were in the placebo group and 79/401 (20%) in the prednisolone group. The relative risk for minor adverse events in the prednisolone group was 1.6 (P = 0.004). Adverse events with a significantly increased risk were acne, fungal infections and gastric pain. Major adverse events were observed in 15/815 patients (2%); 7/414 (2%) in the placebo group and 8/401 (2%) in the prednisolone group. No major adverse events had a significantly increased risk in the prednisolone arm of the trials. No cases of TB were observed in 300 patients who could be followed-up for 24 months. Standardized regimens of corticosteroids for both prophylaxis and treatment of reactions and NFI in leprosy under field conditions in developing countries are safe when a standard pre-treatment examination is performed, treatment for minor conditions can be carried out by field staff, referral for specialized medical care is possible, and sufficient follow-up is done during and after treatment.
机译:麻风病中引起神经功能损害(NFI)的反应通常在田间条件下越来越多地使用皮质类固醇的标准疗法治疗。基于三项研究预防NFI的试验(TRIPOD研究)的数据,出于安全考虑,评估了皮质类固醇的不良事件。在尼泊尔和孟加拉国的麻风控制计划中进行了一项多中心,随机,双盲安慰剂对照试验。按照固定时间表用泼尼松龙治疗16周,从一项试验以20 mg /天(预防方案:总剂量1.96 g)开始,在另两项试验中以40 mg / day(治疗方案:总剂量2.52 g)开始。轻微不良事件被定义为月球面,真菌感染,痤疮和需要抗酸剂的胃痛。主要不良事件定义为精神病,消化性溃疡,青光眼,白内障,糖尿病和高血压。同样,监测感染的足底,手掌和角膜溃疡的发生以及结核病的发生。同时考虑所有三个试验,在130/815例患者中观察到了轻微不良事件(16%)。其中,安慰剂组为51/414(12%),泼尼松龙组为79/401(20%)。泼尼松龙组轻微不良事件的相对风险为1.6(P = 0.004)。发生风险显着增加的不良事件是痤疮,真菌感染和胃痛。在15/815例患者中观察到主要不良事件(2%);安慰剂组为7/414(2%),泼尼松龙组为8/401(2%)。在试验的泼尼松龙组中,没有重大不良事件显着增加风险。 300例患者未观察到结核病病例,可随访24个月。当进行标准的预处理检查时,发展中国家在野外条件下用于预防和治疗麻风的反应和NFI的皮质类固醇的标准化方案是安全的,可以由野外人员进行轻度疾病的治疗,并转介接受专科医疗有可能,并且在治疗期间和之后要进行充分的随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号